Latest News and Press Releases

BOSTON, May 27, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate...

BOSTON, May 08, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, is scheduled to participate in a virtual...

– Regulatory discussions with FDA advance Ziopharm TCR-T IND process –– Enrollment on track in Controlled IL-12 phase 2 clinical trial with Regeneron’s Libtayo®;Controlled IL-12 clinical data update...

BOSTON, April 30, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that it will be presenting data from its Controlled IL-12 program, or Ad-RTS-hIL-12 plus veledimex...

BOSTON, April 27, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, May 7, at 4:30 pm EDT to provide a...

– Emergence of TCR program, Controlled IL-12 data, strengthened team highlight 2019 – – Balance sheet strengthened; cash of approximately $177 million funds operations to mid-2022 – – Clinical trial...

BOSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a...

BOSTON, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that management will host a conference call and webcast on Monday, March 2, at 4:30 p.m. ET to...

BOSTON, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced the pricing of an underwritten public offering of 27,826,086 shares of its common stock at a public...

BOSTON, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that it intends to offer and sell shares of its common stock in an underwritten registered public...